本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Over 30 million GoPay customers can now access Oona Indonesia's affordable health insurance solutions, exclusively on GoPay Asuransi Oona Indonesia continues to boost insurance penetration through strategic digital partnerships and digital innovations JAKARTA, Indonesia, Dec. 3, 2024 /PRNewswire/ -- Oona Insurance Indonesia, a leading digital general insurer in Indonesia, has reached a new milestone by partnering with Indonesia's top digital payment platform, GoPay and leading insurance brokerage firm, Prodigi to expand access to affordable and accessible health insurance solutions for Indonesians. Over 30 million GoPay users can now easily buy simplified health insurance products via GoPay Asuransi, the payment app's first insurance platform with Oona Indonesia as its exclusive insurer. This collaboration represents a pivotal step in Oona Insurance's mission to solidify its presence in the retail health insurance sector. By integrating with GoPay's platform, Oona Indonesia has simplified the insurance purchase process, making it seamless and user-friendly. With GoPay Asuransi, users can quickly select and purchase health insurance by answering a few simple health questions. Personal details are automatically populated from their GoPay profile, eliminating repetitive data entry and ensuring a seamless, hassle-free experience. Payments are seamlessly processed via GoPay for maximum convenience. "This partnership underscores our commitment to leveraging digital innovation to expand our ecosystem and make insurance affordable and accessible to millions of Indonesians. By collaborating with trusted partners like GoPay and Prodigi, we are breaking barriers to insurance access with affordable and simplified products designed for today's digital consumers. GoPay Asuransi fits effortlessly into everyday financial activities, making insurance more accessible to Indonesians than ever before." said Manik Bucha, Group Chief Underwriting Officer, Oona Insurance. "We remain bullish on our growth and will continue forging digital partnerships across different categories to drive insurance penetration and deliver value to our customers," added Manik Bucha, Group Chief Underwriting Officer of Oona Insurance. Kiki Apriyani, Head of Marketing Money Management of GoPay added, "We are excited to partner with Oona Insurance and Prodigi to bring insurance products directly to the GoPay platform, reflecting our commitment to addressing societal challenges and driving financial inclusion. This collaboration is a step toward empowering Indonesians with equitable access to essential financial services. By making health insurance products more accessible and affordable, we aim to enhance financial resilience for GoPay users across Indonesia and look forward to exploring more opportunities with Oona Indonesia to deliver innovative, impactful solutions in the future." GoPay users can choose from GoPay Asuransi two plans powered by Oona Indonesia: Critical Illness Insurance starting at Rp5,000, providing a lump-sum cash payout upon diagnosis of heart attack and cancer with benefits up to Rp100 million, and Health Insurance starting at Rp60,000, offering coverage for ICU, inpatient and outpatient care across 1,300+ hospitals and clinics with an annual limit up to Rp100 million. About Oona Insurance Headquartered in Singapore, Oona Insurance is the leading digital general insurer in Southeast Asia, backed by global private equity firm Warburg Pincus. Established in 2022, Oona Insurance aims to become the general insurer of choice for both partners and customers through a buy-and-build strategy, leveraging the pillars of superior customer service, advanced technology and a well-established brand across Southeast Asia. The firm currently operates in two markets in the region: Indonesia and the Philippines. In Indonesia, Oona operates through its licensed general insurance entity, PT Asuransi Bina Dana Arta, Tbk. Oona Indonesia, the new unified brand of this entity, offers quality products and services since early 2023, serving as a solid foundation for Oona Insurance's expansion across Southeast Asia's fast-growing insurance market. Oona Indonesia is licensed and supervised by Indonesia Financial Services Authority (Otoritas Jasa Keuangan). For more information on Oona Insurance, please visit: www.oona-insurance.com
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). - The approval of XPOVIO® by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland of China, Australia and Singapore. - Additional reimbursements of XPOVIO® in APAC markets are expected. - Antengene has also submitted the new drug applications (NDAs) in additional ASEAN markets, including Thailand, Malaysia and Indonesia, where approvals are expected in the H2 of 2024. SHANGHAI and HONG KONG, June 26, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that South Korea's National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM). The drug is expected to be officially included into the national reimbursed drugs list on July 1, 2024. MM, the second most common hematologic malignancy, is caused by the dysregulated proliferation of plasma cells. Patients with MM face a range of challenges including a high relapse rate, short survival, and limited treatment options. According to market data, the global MM market has exceeded US$17 billion in 2023 and is expected to reach US$ 26 billion by 2028, with a compound annual growth rate (CAGR) of 8.7%[1]. With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor. XPOVIO® has a global commercial presence with approvals in over 40 countries and regions. To date, XPOVIO® has already been included for health insurance coverage in mainland of China, Australia and Singapore in the APAC markets. With the latest approval from the NHIS in South Korea, XPOVIO® is poised to be a novel treatment option and will bring clinically meaningful survival benefits to more patients in need. Antengene has already submitted NDAs for XPOVIO® in Thailand, Malaysia and Indonesia for the treatment of patients with R/R MM and R/R diffuse large B-cell lymphoma (R/R DLBCL). About XPOVIO® (selinexor) XPOVIO® is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses. By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]). About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. Reference: [1] Global Multiple Myeloma Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation), by Region, and Segment Forecasts, 2023-2028. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.com Mobile: +86 13062747000
SHANGHAI, Jan. 18, 2024 /PRNewswire/ -- Leapstack, a prominent insurtech company, recently secured an impressive 200 million RMB yuan in Series C+ Funding, led by Qiming Venture Partners. The funding round also saw active participation from Soochow Yihe Capital, and existing shareholder Legend Capital, with exclusive financial advisory services provided by MountainView Capital. As a technology-driven enterprise, Leapstack specializes in cutting-edge digital solutions for medical insurance. The company offers comprehensive digital solutions catering to government health insurance departments, commercial insurance companies, medical/nursing institutions, as well as pharmaceutical and medical device companies, among other enterprises. Since its establishment in 2016, Leapstack has successfully completed multiple funding rounds, boasting a robust shareholder portfolio that includes Gaorong Capital, Fomou Assets, DCM, Puhua Capital, Danhua Capital, Lingfeng Capital, FinVolution Group (NYSE: FINV), Uphonest Capital, 360 DigiTech (NASDAQ: QFIN), Legend Capital, Peakview Capital, GF Qianhe Investment and Huazhi Capital, etc. The growing urbanization, changes in the aging population structure, as well as the increase in both medical expenses and health insurance awareness, have resulted in the continuous rise of rigid demand for health insurance in China. In this context, the insurance industry, especially health insurance, is undergoing the digital transformation, with an active participation of technology enterprises in becoming more "automated." Technologies like artificial intelligence and big data are changing the entire value chain, including product development, pricing, distribution, operations, underwriting, and claims processing. In 2022, the premiums for health insurance in China reached 865.2 billion yuan. Such a substantial market size underscores the essential need for corresponding digital services, making it imperative for insurtech enterprises to seize opportunities strategically. In addition, it attracts attention from all parts of the industry towards how to accelerate a successful digital transformation of medical insurance and commercial insurance. Taking the innovation and expansion of business as an example. With the continual exploration and implementation of cutting-edge technologies and the dynamic shifts in consumer trends, new consumer demands are driving fundamental changes in health insurance types, product content, business models, and industry ecosystems. As one of the technology enterprises that started digital transformation of health insurance early, Leapstack has consistently prioritized cost control and digital services at the core of its business strategy. On one hand, Leapstack has developed an intelligent audit system. Through the establishment of an in-house medical insurance fund supervision team, it employs a smart online audit + random offline inspection to serve as a robust safeguard for the public's medical expenses. On the other hand, for digital services, Leapstack furnishes commercial insurance enterprises with an all-encompassing digital platform. Leveraging its in-house automated operation engine, seamlessly integrated with big data risk analysis, Leapstack establishes a closed loop of efficiency and fee control. This empowers the entire insurance claims process, resulting in reduced costs and increased efficiency. It is reported that Leapstack has been actively involved in the medical insurance supervision programs led by the government, including major supervision programs for medical insurance fund at the national or provincial level, the operation welfare projects in dozens of cities, and the operation services for long-term care. Up till now, it has served medical insurance bureaus and relevant regulatory agencies in over ten provinces and 100+ cities across the country, allowing the public to access more convenient, fair and accessible medical insurance services. In comparison to a decade ago, the insurance industry has undergone a revolutionary transformation in digitization. With the growth of the health insurance market and policy incentives, there is an increasingly prominent application demand for big data, cloud computing, robotic process automation (RPA), and large-scale modeling technologies in this sector. Leapstack, holding its position in the development, dedicates itself to health insurance. It pioneers the model of "digital risk control for health insurance," effectively facilitating the digital integration of policy-based medical insurance and commercial health insurance. By bridging actuarial, product design, underwriting, claims process, customer service, and other operational processes, it achieves collaborative dynamic risk control throughout the product lifecycle. Such digital empowerment facilitates innovative product design, rational pricing, and refined operations. Over several years of dedicated development, Leapstack has centered its efforts on addressing the specific needs of the insurance business. This commitment has culminated in the comprehensive creation of a range of data products, including a big data risk control system for health insurance, a processing system for long-term care insurance, a service system for critical illness medical insurance, a claims system for commercial health insurance, and a chronic disease management system for health insurance. As Leapstack empowers digital services in government medical insurance and commercial insurance through technological advancements, it is concurrently pursuing expansion into the medical care and health industry. Through the integration of the enterprise, medical, and pharmaceutical scenarios, and the connection among quality medical resources, Leapstack aims to achieve effective access to quality medical services and innovative diagnosis and treatment solutions. By innovating payment methods, Leapstack contributes to the enhancement of effective and quality medical services, progressively improving health guarantees. In response to the expanding market and rapid business growth, Leapstack has successfully concluded product development and solution construction for various business scenarios. At the same time, as a pioneer in China's insurtech sector exploring international markets, Leapstack has launched its business in Vietnam, Indonesia and other markets over the past two years. As outlined in its strategic roadmap, Leapstack envisions a substantial expansion of its overseas business over the next three to five years. Leapstack is poised to make an entry into the Thai and Singaporean markets, aiming to spearhead technological integration throughout the entire Southeast Asian region through the implementation of innovative business models. Throughout the process of high-quality development, Leapstack remains true to its original mission, persistently aligning with the national strategic direction. In the Health 3.0 era, insurance and medical services will go hand-in-hand to finish digital transformation, and the business models become multidimensional. With a sound domestic market share and its expansion in the overseas market, Leapstack is sure to gain new impetus for furthering its insurance business in the Asia-Pacific market. Going ahead, Leapstack will continue to play a pivotal role in transforming health insurance, advancing the development of robust big data models, and improving comprehensive operational services. Through these efforts, Leapstack remains committed to becoming a world-class technology platform for insurance, leveraging technologies to safeguard health guarantee.
SHANGHAI, Jan. 18, 2024 /PRNewswire/ -- Leapstack, a prominent insurtech company, recently secured an impressive 200 million RMB yuan in Series C+ Funding, led by Qiming Venture Partners. The funding round also saw active participation from Soochow Yihe Capital, and existing shareholder Legend Capital, with exclusive financial advisory services provided by MountainView Capital. As a technology-driven enterprise, Leapstack specializes in cutting-edge digital solutions for medical insurance. The company offers comprehensive digital solutions catering to government health insurance departments, commercial insurance companies, medical/nursing institutions, as well as pharmaceutical and medical device companies, among other enterprises. Leapstack has consistently prioritized cost control and digital services at the core of its business strategy. On one hand, Leapstack has developed an intelligent audit system. Through the establishment of an in-house medical insurance fund supervision team, it employs a smart online audit and random offline inspection to serve as a robust safeguard for the public's medical expenses. On the other hand, for digital services, Leapstack furnishes commercial insurance enterprises with an all-encompassing digital platform. Leveraging its in-house automated operation engine, seamlessly integrated with big data risk analysis, Leapstack establishes a closed loop of efficiency and fee control. This empowers the entire insurance claims process, resulting in reduced costs and increased efficiency. Leapstack has launched its business in Vietnam, Indonesia and other markets over the past two years. As outlined in its strategic roadmap, Leapstack envisions a substantial expansion of its overseas business over the next three to five years. Leapstack is poised to enter the Thai and Singaporean markets, aiming to spearhead technological integration throughout the entire Southeast Asian region through the implementation of innovative business models. Leapstack is concurrently pursuing expansion into the medical care and health industry. Through the integration of the enterprise, medical, and pharmaceutical scenarios, and the connection among quality medical resources, Leapstack aims to achieve effective access to quality medical services and innovative diagnosis and treatment solutions. By innovating payment methods, Leapstack contributes to the enhancement of effective and quality medical services, progressively improving health guarantees. Since its establishment in 2016, Leapstack has successfully completed multiple funding rounds, boasting a robust shareholder portfolio that includes Gaorong Capital, Fomou Assets, DCM, Puhua Capital, Danhua Capital, Lingfeng Capital, FinVolution Group (NYSE: FINV), Uphonest Capital, 360 DigiTech (NASDAQ: QFIN), Legend Capital, Peakview Capital, GF Qianhe Investment and Huazhi Capital, etc.
HONG KONG, Nov. 30, 2023 /PRNewswire/ -- Alea, Hong Kong's leading health insurance & benefits broker and IMI, Asia's largest natural and integrated medicine clinic, have announced the formation of a partnership to better serve clients on their healthcare needs. This partnership will see Alea offer unbiased, personalised insurance advice to IMI patients, while IMI will provide high-quality health information and services to Alea's clients and community. From digital health content to expert tips and wellbeing perks, this collaboration will empower individuals and employees to make informed decisions about their health, from prevention to protection. Beyond individual & families, this collaboration will extend to corporate wellness, where Alea and IMI will join forces to offer added-value wellbeing services that benefit HR professionals, employees and companies as a whole. Navigating healthcare and insurance options can be challenging and confusing. Alea has developed a unique expertise in helping clients find the best medical insurance options in areas like complementary medicines, maternity, women's health or mental health. This knowledge is complemented by IMI's award-winning individual and business wellness solutions – designed to enable patients to live healthy, happy and well. "We are thrilled to work with a partner like IMI. We have known IMI for a long time and see real synergies between our two organisations" says Julien Mathieu, Co-Founder of Alea. Dr Benita Perch, IMI Managing Director, adds "We are proud of this partnership with Alea. We both provide highly personalised and confidential services to help people take control of their health. We share the same values, starting with empathy and a human touch". For media inquiries, please contact: Alea Marketing and PR DepartmentTel: +852 2606 2668Email: hello@alea.care About Alea Alea reinvents the health insurance experience for individuals, families and companies by offering unbiased advice, simplicity and a human touch. Every day, Alea compares hundreds of local and international insurance options from 25+ trusted partners like Allianz, AXA, APRIL, Bupa, Cigna, FWD, MSH and more. Alea's distinct approach includes deep healthcare knowledge and award-winning customer care. Through its sister company Healthy Matters, Hong Kong's #1 health platform, Alea develops a unique community with exclusive wellness content and resources backed by top health professionals, on topics like maternity, mental health, parenting. For more information about Alea, visit https://alea.care/ About IMI Trusted and respected by thousands, Integrated Medicine Institute (IMI) is the largest alternative health clinic in Hong Kong and Asia. Since 1990, IMI has helped people enjoy optimal health and wellbeing through an unparalleled range of specialist services, treatments, and diagnostic and functional medicine testing. In 2019, IMI launched IMI Corporate Wellness – a comprehensive programme led by experienced doctors and wellness practitioners to address every facet of professional wellness and cultivate healthy, thriving organisations. IMI's guiding philosophy is to support you to Heal, Balance, Evolve. For more information, visit https://www.imi.com.hk/
HONG KONG, Oct. 11, 2023 /PRNewswire/ -- Health insurance is a critical aspect of financial planning, ensuring that individuals and families have access to quality healthcare without the burden of exorbitant medical expenses. In Hong Kong, where the cost of healthcare can be quite high, finding the right health insurance plan is essential. Fortunately, NowCompare.com.hk has been helping Hong Kong save money since 2009, while ensuring access to top-notch healthcare services. NowCompare.com.hk stands out as the best way for Hong Kong people to save money on health insurance. NowCompare is designed to make the often-complicated process of comparing and selecting health insurance plans easy and accessible to everyone. But what sets NowCompare.com.hk apart from the rest? First and foremost, NowCompare Hong Kong collaborates with the best health insurance providers in the market. This extensive network of partnerships ensures that customers have access to a wide range of insurance options, allowing them to choose the plan that best suits their needs and budget. Whether you're looking for comprehensive coverage or a more budget-friendly option, NowCompare.com.hk has you covered. Additionally, NowCompare offers personalized assistance to help users find the perfect health insurance plan. Their team of experts understands the unique needs and preferences of Hong Kong residents, and they are dedicated to helping customers navigate the complex world of insurance. This level of support ensures that you get the coverage you need without overspending. Moreover, NowCompare.com.hk is committed to transparency and honesty. There are no hidden fees or surprises when you use them. You'll receive clear and concise information about each insurance plan, allowing you to make decisions with confidence. In conclusion, health insurance is a crucial investment in your well-being and financial security, and since 2009 NowCompare.com.hk is the best way to save money in Hong Kong. With its extensive network of top providers, personalized assistance, and commitment to transparency, it's clear that NowCompare Hong Kong is the leader in the market. Don't wait to secure your health and financial future – visit NowCompare.com.hk today and find the perfect health insurance plan for you and your family.
A12 藝術空間
Health Insurance
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
